In addition, the ERK inhibitor temuterkib has shown promise in BRAF- and KRAS-mutant pancreatic cancer models, tested alone or in combination with HCQ (NCT04386057), and paricalcitol and HCQ or in combination with GnP (NCT04524702) in advanced or mPDAC patients. The gene discussed is KRAS; the disease is pancreatic neoplasm.